Roche GLP-1 produces “robust” weight loss in late-stage obesity trial
The pharma company’s injectable GLP-1/GIP receptor agonist CT-388 is an important element of its weight loss strategy and also delivered benefits for pre-diabetic patients.
List view / Grid view
The pharma company’s injectable GLP-1/GIP receptor agonist CT-388 is an important element of its weight loss strategy and also delivered benefits for pre-diabetic patients.
Conclusion of ‘landmark’ deal significantly enhances trade, investment and supply chains, notably granting beneficial tariff reductions for the pharma industry.
Phase II data derived from the first randomised trial comparing immunotherapy outcomes post-FMT from immunotherapy responders versus placebo.
Disrupting drug-resistant Gram-negative pathogens is a potential breakthrough in addressing AMR and enhancing antibiotic success.
He brings 30 years of pharma industry experience to the role, principally in key manufacturing projects.
CGT Catapult research shows an increase in phase I/II trials, led by oncology but with clear growth in other disease areas such as inflammation.
The CRDMO will support the biotech company’s work on next-generation immunotherapies for oncology and autoimmune diseases.
Study highlights potential of novel system for continuous, automated production of albuterol sulfate, an API on the US FDA’s drug shortage list.
Achieves 100 percent response in phase II data highlighting HT-001's potential as a supportive oncology treatment to address a common EGFR therapy burden.
New phase IIb data highlights the combination’s potential to offer improved efficiency to high-risk melanoma patients.
The East Coast expansion is part of the biopharma firm’s $50 billion investment in its US manufacturing and R&D capabilities.
EU Parliament agrees clear priorities for future negotiations on the act, including investing in pharma manufacturing capacity.
Will gain access to ozureprubart, a potential best-in-class antibody for food allergies, and expand its respiratory, immunology and inflammation pipeline.
Research findings support the design of robust microbial processes for pharmaceutical products.
European pharma industry acknowledges the progress made, particularly with partial tariff reductions, but said further provisions could have been achieved.